Highlights  Synthesis of 23 novel deshydroxy bicalutamide derivatives.  Identification of novel and potent double branched AR antagonists.  Enhanced anticancer activity against PC compared to bicalutamide and enzalutamide.  Strong downregulation of PSA expression in qPCR analysis of LnCaP cell line.  Molecular modelling provides a rational explanation of the SAR observed.
Introduction
The androgen receptor (AR) is expressed in many cell types and plays critical anabolic and reproductive roles in men and women. Androgen receptor (AR) signalling has been found to play crucial functions in modulating tumourigenesis and metastasis in several types of cancers including prostate, bladder, kidney, lung, breast and liver. 1 The initiation and progression throughout the different stages of prostate cancer (PC) is uniquely dependent on the androgen receptor (AR) signalling pathway. 2, 3 Androgen receptor (AR), like other members of the nuclear receptor family, is comprised of three main functional domains: a variable N-terminal domain, a highly conserved DNA-binding domain (DBD) and a conserved ligand binding domain (LBD). 4 Binding of endogenous hormones; testosterone and dihydrotestosterone (DHT) to the LBD induces conformational changes in the AR that results in its translocation into the nucleus, interaction with DNA, and modulation of specific gene transcription (e.g. prostate specific antigen, PSA). 5 Androgen receptor antagonists, so-called anti-androgens, are designed to inhibit these processes and are clinically used for the treatment of advanced prostate cancer (PC). 6, 7 Several non-steroidal anti-androgens (NSAA) have been approved for the treatment of PC. The first generation NSAAs include flutamide, hydroxyflutamide, nilutamide and bicalutamide (Figure 1) . They decrease androgenic effects by competitively inhibiting the binding of androgens (testosterone and DHT) to the AR and induce conformational change of H12 via steric clashes. However, these antiandrogens eventually fail to inhibit the AR with the development of castration resistant prostate cancer (CRPC). The development of AR-LBD point mutants (e.g. AR-T877A and AR-W741L) upon long term treatment with NSAAs ultimately result in switching these AR antagonists to AR agonists leading to the relapse of CRPC, which is a more aggressive form of the disease associated with poor prognosis. Similar to the first-generation androgen receptor (AR) antagonists, resistance to the new second generation anti-androgens (enzalutamide, apalutamide) are developing in PC patients, despite the fact that these drugs have better affinity for the AR. 8 Anti-androgen resistance can also be triggered by the upregulation of the androgen receptor expression, which promotes signalling from low levels of residual hormone. 8 More recently, darolutamide (ODM-201, Figure 1 ) is under evaluation in phase 3 clinical trials in patients with non-metastatic CRPC. 9 The discovery of new AR antagonists is urgently needed to improve anti-androgen efficacy and to avoid cross-resistance with the clinically used compounds. 
Results and discussion
Unfortunately, resistance to clinical anti-androgens has plagued the development of effective therapeutics for advanced prostatecancer (PC). Flutamide and bicalutamide (Figure 1) were first generation non-steroidal AR antagonists. However, these antiandrogens lose their activity with time upon the development of AR-LBD point mutants (AR-T877A and AR-W741L) triggered by flutamide and bicalutamide, respectively. On the other hand, AR-F876L mutation causes enzalutamide and apalutamide (ARN-509) to function as AR agonists and confers drug resistance across multiple AR models both in vitro and in vivo. 10 The X-ray structure of bicalutamide inside the LBD site of the AR -W741L mutant, (PDB 1Z95), provides a significant insight into the protein−drug interactions and explains the structural basis for the conversion of bicalutamide from AR antagonist into AR agonist. 10, 11 The binding mode of bicalutamide as an antagonist of the AR-wild type compared to its binding mode as an agonist of the AR-W741L mutant is shown in Figure 2 . It is observed that helix 12 (H12) has changed its position from an open antagonist conformation (AR-wild type, blue) to a closed agonist conformation (AR-W741L mutant, green). In the case of the antagonist mode, ring B of bicalutamide is pointing outwards away from Trp 741 and towards helix 12, thus preventing AR from adapting the closed AR agonist conformation. The loss of the steric bulk of the indolyl side chain of tryptophan 741 to the smaller size side chain of Leucine 741 lead to the elimination of the steric clash and hence the incorporation of bicalutamide molecule into the closed activated conformation of AR. [10] [11] [12] Figure 2. Proposed structural basis for the conversion of bicalutamide from AR antagonist into AR agonist by the gain-offunction mutation (W741L); the X-ray structure of bicalutamide (green) inside the closed agonist conformation of AR LBD-W741L, (green, PDB 1Z95) compared to its binding mode (blue) inside the open antagonist conformation of AR LBD-wt, showing ring B orientation to hinder helix 12 from closing to an agonist conformation.
From previous studies, we have learnt that the size and structure of ring B determine the activity of the anti-androgen and if possesses the correct volume and orientation, it will prevent the antiandrogen molecule from being completely confined in the AR-LBD pocket cavity, leaving its bulky substituents protruding against helix 12 (H12) and stopping the latter from adopting a position essential for coactivator interaction (agonist closed conformation). [10] [11] [12] Previously, we have found that the introduction of 3,5-bis-trifluoromethyl (3,5-bis-CF3) substituents into ring B of bicalutamide, enobosarm and umbelliferone derivatives, has profoundly modified their anti-proliferative activity, pharmacokinetic and tissue distribution profiles by providing the geometric bulk needed to keep ring B towards Helix 12 while keeping the crucial interactions of the nitrile/nitro group of ring A with Arg 752. [13] [14] [15] Noting that both flutamide and darolutamide (ODM-201) are lacking the linker OH group, Figure 1 , in this work we studied whether the central hydroxyl group of bicalutamide is necessary for maintaining the anti-androgen activity and if the successive increase in the bulk size of ring B substituents (from 4-F  4-CF3  3,5-bis-CF3) would compensate for the smaller size of the deshydroxy linker (lacking the central OH group). We used four different variations of aromatic ring A (Figure 3) ; all containing the necessary 4-CN or 4-NO2 for the interaction with Arg 752 in addition to either 2-CF3 or 3-CF3 substituent to understand better the structure activity relationship. 
Chemistry
The novel series of deshydroxy propioanilide analogues (29-41) were synthesised in three steps. An acylation reaction between the corresponding substituted trifluoromethyl anilines (1-4) with methacryloyl chloride (5) in dimethylacetamide (DMA) to obtain phenylmethacrylamide derivatives (6-9) 16, 17 was followed by Michael addition of the corresponding substituted thiophenols (10-13) to obtain the thioether intermediates (14-26, 19-56% yield), which were subsequently oxidised to the corresponding sulfone derivatives (29-41, 19-95% yield) using 3-chloroperbenzoic acid (mCPBA) (Scheme 1). It is worth noting that the thioethers (14-20 and 24-26) were prepared using sodium hydride (NaH) in tetrahydrofuran (THF) at room temperature (method A), whereas the thioethers (21-
23)
corresponding to the N-(4-cyano-2-(trifluoromethyl)phenyl) methacrylamide (8) were prepared using aqueous sodium hydroxide solution and tetrabutylammonium chloride in 1,4-dioxane and reflux for 3 hours instead (method B), as the first method did not yield any products. 18 The mechanism of the formation of the double branched products remains to be fully clarified. All compounds were purified by column chromatography and/or recrystallised. The structures of all the synthesised compounds were confirmed using analytical and spectroscopic data ( 1 H NMR, 13 C NMR, 19 F NMR and mass spectrometry), which were in full accordance with their depicted structures. 
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Docking studies reveal a structural basis for anti-androgen activity
Previous X-ray crystallographic studies of androgen receptor have elucidated the structures of the AR ligand binding domain (LBD) bound to agonists, and of mutant AR bound to antagonists in an agonist like conformation. However, there are no crystal structures of the AR-LBD in an antagonist conformation reported so far. 22, 23 The human progesterone receptor (hPR residues 683-931) has 56% primary sequence homology to the hAR (residues 669-918) and 32% of these residues are conservative mutations, giving an overall sequence homology of 87%. 24 Building on this information, the hPR crystal structure [PDB 2OVH] 25 was used as a template to build an hAR homology model (HM) using the sequence of the hAR in the agonist conformation [PDB 2AMA]. 26 Applying the default parameters of MOE (Molecular Operating Environment -Chemical Computing Group, Montreal, Canada) homology modelling module and using the AMBER99 force field, a total of 10 homology models were generated.
The quality of each model was assessed within MOE, and the best model was chosen for the docking studies.
Computational docking studies were performed to explore the binding modes of the deshydroxy propioanilide analogues (14-41) within the AR-LBD binding site. The chemical structures of our compounds (14-41) were constructed, rendered and minimized with the MMFF94x force field in MOE.
Docking simulations were performed using Glide SP in Maestro (Glide, version 9.5, Schrödinger, LLC, 
Conclusion
General method for the preparation of intermediates 6-9
Methacryloyl (8) The corresponding thiophenol 10-13 (2.05 mmol) was added dropwise to an aqueous sodium hydroxide solution (79 mg in 1 ml water) for 15 min at room temperature. Then a solution of compound 8 (2.05 mmol) in 1,4-dioxan (5 mL) was added at room temperature followed by a catalytic amount of tetrabutylammonium bromide. The reaction mixture was refluxed for 3 h and cooled to room temperature, followed by addition of 26% aqueous acetic acid. This mixture was extracted with ethyl acetate (2 x 200 mL). The ethyl acetate layer was separated, washed with water, and concentrated under reduced pressure. The crude residue was purified by column chromatography eluting with chloroform-ethyl acetate gradually increasing from 95:5 to 90:10 v/v. (14) . Yield; (18) . Yield; 45 (19 
N-(4-cyano-2-(trifluoromethyl)phenyl)methacrylamide
N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)thio)-2-methylpropanamide
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-3-((3-(trifluoromethoxy)phenyl)thio) propanamide
3-((4-Fluorophenyl)thio)-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide
2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-((4-(trifluoromethyl)phenyl)thio)propanamide
3-((3,5-Bis(trifluoromethyl)phenyl)thio)-N-(4-cyano-2-(trifluoromethyl)phenyl)-2-methyl
propanamide (23 
3-((4-Fluorophenyl)thio)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)propanamide (24). Yield; 49
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-2,3-bis((4-(trifluoromethyl)phenyl)thio)
propanamide ( 
2,3-Bis((3,5-bis(trifluoromethyl)phenyl)thio)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)
propanamide (28 
General method for the preparation of sulfones derivatives 29-41
To a stirring solution of the corresponding sulfide 14-26 (0.7 mmol) in 5 mL anhydrous dichloromethane, was added 3-chloroperbenzoic acid (MCPBA) (1.4 mmol) . The solution was stirred at room temperature for 24 h. The reaction mixture was neutralized with 1M sodium hydroxide. 50 mL distilled water was added to the reaction mixture and was extracted with 2 x 50mL of dichloromethane.
The combined organic layers were washed, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude residue was purified by column chromatography, preparative TLC or crystallization from methanol.
N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-methylpropanamide (29).
Yield; 69% 
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-3-((4-(trifluoromethyl)phenyl)sulfonyl)
propanamide ( N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-3-((3-(trifluoromethoxy) N-(4-cyano-2-(trifluoromethyl)phenyl)-3-((4-fluorophenyl) 
N-(4-cyano-2-(trifluoromethyl)phenyl)-2-methyl-3-((4-(trifluoromethyl)phenyl)sulfonyl)
In vitro cell based assay
Cell culture
All cells were cultured in T75 flasks in a humidified atmosphere of 5% CO2 at 37°C. LNCaP cells were cultured in RPMI-1640 medium, PC3 and VCaP cells in DMEM, all supplemented with 10% FCS and antibiotics (penicillin 100U/ml and streptomycin 100μg).
Anti-androgen treatment in vitro
Bicalutamide and enzalutamide were used as positive controls (used as the clinical standard) in LNCaP, PC3 and VCaP cells, and DMSO was used as a vehicle control. Nine 1⁄2 serial dilutions of 10 mM bicalutamide stock were made in 50 μL of DMSO to give nine increasing concentrations from 0.1 μM to 100 μM. All novel deshydroxy compounds were tested in LNCaP cells, and compounds 27, 28 and 33
were subsequently tested in PC3 and VCaP cells because of their low IC50 values.
PC3 and LNCaP cells were plated in a 96-well plate (4000cells/well) and then incubated overnight to adhere. Each drug concentration (0-100uM) was then added in sequence to ten tubes of fresh media to achieve a 1:100 dilution. The old medium was then gently removed and replaced with 200 μL of fresh media containing the nine increasing drug concentrations and the DMSO control, in triplicate.
Following 96 hours of incubation the samples were tested with the MTT or MTS assay. The IC50 was then calculated from the mean of these triplicate values and dose-response curves were plotted. VCaP cells were treated as above, with the following exceptions. The novel compounds were diluted 1:50, only 100 μL of the old medium was extracted and it was replaced with 100 μL of the novel compound in media. This was done to avoid removing the cells from the 96-well plates in view of their poor adherence.
MTT and MTS assays
Colorimetric MTT (LNCaP and PC3) and MTS (VCaP) assays were used to determine cell viability following in vitro anti-androgen treatment. 20μL (1/10th well volume) of MTT or MTS were added to the wells as appropriate. MTS absorbance was recorded at 490 nm by the Elx800TM microplate reader after 1 and 2-hours of incubation. For the MTT assay, following the appearance of purple formazan crystals under the light microscope, the medium was then carefully removed and the formazan crystals dissolved in 200 μL of acidified isopropanol and MTT absorbance was recorded at 540nm on the Elx800TM microplate reader. Percentage cell viability was normalised to the DMSO control.
Statistics
Cell number-MTT correlations and IC50 values were calculated from the mean of three replicates using Microsoft Excel and GraphPad Prism v6.01 (GraphPad Software, Inc., San Diego, CA). Cell number-MTT correlations were analysed by linear regression, whereas IC50 values were produced through non-linear regression. qPCR results were analysed using the ΔΔCT method in Excel. Mean IC50 values were then analysed for statistical significance (p=<0.05) compared to bicalutamide and enzalutamide using GraphPad Prism v6.01 with consideration to the OECD guidelines.
One-way analysis of variance (ANOVA) followed by Tukey's Honest Significant Difference test analysed 
PSA Expression and androgen inhibition qPCR experiments
LNCaP cells were trypsinised and re-suspended in 13ml of RPMI. 0.5ml of this cell suspension was then added to individual wells in 6-well plates with 3 ml of fresh RPMI, and the cells incubated for 24-hours to adhere. Two individual wells in each plate received no treatment and DMSO at a 1:100 dilution as negative controls. The 6-well plates used to analyse PSA expression by qPCR then were treated with 5, 10, 50 and 100 μM of bicalutamide, compounds 27, 28 and 33, followed by 24-hours incubation.
RNA Isolation
RNA isolation was carried out in the six-well plates using the Sigma procedure. The media was gently removed, 1ml of TRI-reagent added per sample and the viscous lysate containing DNA, RNA and proteins transferred to 1.5ml Eppendorf tubes. 200μl of 1-bromo-3-chloropropane was then added, the Eppendorf tubes vortexed, left to stand for 5 minutes and stored at -80°C. The samples were then warmed to room temperature, vortexed and centrifuged at 12,000 x g for 15 minutes at 4°C to solubilise the RNA in the upper, colourless aqueous phase. The samples were then kept on ice, the aqueous phase transferred to fresh Eppendorf tubes and 0.5ml of isopropanol added. The tubes were then vortexed, left to stand for 5 minutes and centrifuged at 12,000 x g for 10 minutes at 4°C in order to recover the RNA pellet. After removing the supernatant, the pellet was washed with 1ml of 75% ethanol, vortexed and centrifuged at 7500 x g for 5 minutes at 4°C. After this, ethanol was carefully removed, the samples briefly air-dried for 5-10 minutes and the RNA pellet dissolved with 20μl of RNAse-free PCR water. The RNA concentration was then measured in ng/μl by recording the absorption of each 1μl sample at 260nm on the Implen NanoPhotometer against nuclease-free water as a control.
The samples were then stored at -80°C for 24 hours.
Complementary DNA synthesis (cDNA)
The RNA samples were uniformly diluted to 50ng/μl on ice. 10 μl of RNA and 10 μl of RT mix were then centrally added to a 96-well non-skirted PCR plate on ice, thermosealed and centrifuged up to 1000rpm in the Grant bio LMC-3000. The components of the RT mix are shown below: The samples were then placed in the Simpli-Amp thermal cycler under the following conditions: 25°C for 5 minutes, 42°C for 60 minutes, 70°C for 15 minutes, and 4°C. The samples were then stored at -20°C overnight.
Quantitative polymerase chain reaction (qPCR)
qPCR was performed in triplicate to analyse the LNCaP cells for relative PSA gene expression. The PSA primer was run alongside the AR, GAPDH, RPL19 and B-actin as housekeeping genes in order to normalise the data and validate the results. These forward and reverse primer pairs were briefly thawed and vortexed, diluted 1:40 with RNAse-free PCR water in four 1.5ml Eppendorf tubes, and returned to ice. Following this, the cDNA was diluted in 20μl of RNAse-free PCR water. 40ul of this diluted cDNA was then transferred into 0.5ml Eppendorf tubes and kept on ice. 2ul of this diluted cDNA was added to individual wells of an optical qPCR 96-well plate, followed by 8μl of the PCR mix. The qPCR plate was then thermosealed, centrifuged up to 1000rpm in the Grant bio LMC-3000, and loaded into the StepOnePlus real-time PCR system. The PCR reaction volume was 10μl, and 50 cycles were performed within the standard 2-hour cycle.
